Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy

Rhea-AI Filing Summary

Thermopylae Holdings Ltd., a major shareholder of AbCellera Biologics Inc., reported an open-market purchase of 177,457 common shares at a weighted-average price of $3.27 per share. The filing notes the trades occurred in multiple transactions between $3.19 and $3.40, bringing Thermopylae’s holdings to 56,096,097 common shares.

Insider Trade Summary

Net Buyer: 177,457 shares ($580,284)

Net Buy 1 txn

Insider Thermopylae Holdings Ltd.

Role 10% Owner

Bought 177,457 shs ($580K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	177,457	$3.27	$580K

Holdings After Transaction: Common Shares — 56,096,097 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thermopylae Holdings Ltd.

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER A1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/26/2026		P	V	177,457	A	$3.27(1)	56,096,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $3.19 to $3.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Remarks:

	Tryn Stimart, attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Thermopylae Holdings report for ABCL?

Thermopylae Holdings Ltd. reported buying 177,457 AbCellera Biologics common shares in the open market. The weighted-average purchase price was $3.27 per share, reflecting multiple trades executed within a disclosed price range during the same trading day.

At what prices did Thermopylae Holdings buy AbCellera (ABCL) shares?

Thermopylae’s AbCellera purchases were executed between $3.19 and $3.40 per share. The weighted-average price across all 177,457 shares was $3.27, according to the filing footnote detailing the range of individual transaction prices.

How many AbCellera (ABCL) shares does Thermopylae Holdings own after this transaction?

After the reported purchases, Thermopylae Holdings beneficially owns 56,096,097 AbCellera common shares. This total reflects the new shares acquired in the open-market transactions added to its previously held position as disclosed in the ownership column.

Was the AbCellera (ABCL) insider transaction a purchase or a sale?

The AbCellera insider activity was a purchase. Thermopylae Holdings Ltd. executed an open-market buy of 177,457 common shares, classified under transaction code “P,” which denotes a purchase in an open market or private transaction.

Who is the reporting person in the latest AbCellera (ABCL) Form 4?

The reporting person is Thermopylae Holdings Ltd., identified as a ten percent owner of AbCellera Biologics. The Form 4 attributes the open-market purchase of 177,457 common shares directly to this entity rather than to any individual insider.